April 21, 2021
1 min read
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
TTP399, an oral glucokinase activator for one-time oral testing, received the FDA’s pioneering therapeutic designation as an add-on therapy to insulin for patients with type 1 diabetes. It was the top story in endocrinology last week.
Another top story revealed a possible way to predict when women will start menopause. Using Cox models with time-dependent covariates associated with age in natural menopause, the researchers determined the age for Finnish participants.
Source: Adobe Stock
Read these and other top stories in endocrinology below:
The FDA grants a breakthrough therapeutic designation for a novel type 1 diabetes pill
According to a press release from vTv Therapeutics, the FDA awarded TTP399 a breakthrough therapy as an add-on therapy to insulin for the treatment of type 1 diabetes. Continue reading.
Lifestyle, socio-economic factors help predict natural age menopause
Menopausal indicators such as follicle-stimulating hormone and estradiol levels combined with lifestyle habits and socio-economic factors can help predict when a woman will start menopause, according to study data. Continue reading.
Natural menopause occurs 1.5 years later than in 1959
The median age for natural menopause and median reproductive life spans increased over a 60 year period from 1959 to 2018, according to a research letter for women published in JAMA. Continue reading.
Dapagliflozin Cannot Prevent Organ Damage, Death In Adults Hospitalized With COVID-.19th
Top-line data from the Phase 3 DARE-19 study shows that the SGLT2 inhibitor dapagliflozin failed to prevent organ dysfunction and all-cause mortality in hospitalized patients with COVID-19 who are at risk of serious complications. Continue reading.
Black, Asian, female patients are less likely to receive an SGLT2 inhibitor recipe
Black, Asian, and female patients with type 2 diabetes are less likely to receive a prescription for an SGLT2 inhibitor than other groups, even if they have been diagnosed with cardiovascular or kidney disease. This shows a database analysis. Continue reading.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio